Home Blog Page 1578

China’s REIT Market Accelerates Growth, Signaling a New Era for Real Estate Investment

By
Advertorial Desk
-

Cushman & Wakefield Experts Share Market Insights at MIPIM Asia Summit


HONG KONG SAR – Media OutReach Newswire – 4 December 2025 – China’s Real Estate Investment Trust (C-REIT) market is entering a transformative phase, marked by rapid expansion in issuance size, diversification into emerging asset classes, and rising institutional investor confidence. Since its inception, the market has grown to reach a total issuance scale of RMB207 billion across 77 projects as of end of November, underscoring its growing maturity and strategic importance.

Cushman & Wakefield subject matter experts shared these insights at the MIPIM Asia Summit held in Hong Kong over December 3–4, highlighting the firm’s leadership in shaping the sector. To date, Cushman & Wakefield has advised on IPOs and subsequent expansions for 46 C-REITs, including nine of China’s twelve listed Retail REITs such as the recent IPO of CapitaLand Commercial China-REIT, reinforcing its dominant position in this evolving market.

Francis Li, International Director, Head of Capital Markets, Greater China, said, “China’s REIT market has demonstrated remarkable growth, expanding its market value by approximately 85% last year and securing a position among the top three REIT markets in Asia for the first time in 2024. However, with only four years of history, the C-REIT market remains relatively young compared to mature markets such as the U.S. and Japan, which highlights significant potential for future growth as the market matures and diversifies to include a broader range of investors and asset classes.

“The participation of individual investors will be pivotal in driving the development of the C-REIT market. With household savings in China exceeding RMB160 trillion (around US$22 trillion), there is immense opportunity to channel these funds into the REIT market. The Central Government’s 15th Five-Year Plan, which focuses on optimizing policies in education, healthcare, and social security, is expected to boost domestic consumption and enhance the overall financial market. This, in turn, will likely improve the liquidity of the C-REIT market, enabling it to play a more significant role in the recovery of China’s commercial real estate sector.”

Recent developments have demonstrated notable acceleration in market activity, particularly within the real estate (RE) C-REIT segment, which now accounts for 54% of the total issuance size. Expansion into sectors such as retail, rental housing, and logistics has been a primary driver of this growth. The retail sector, in particular, has seen 12 listings, raising a total of RMB30.3 billion. Strong secondary market performance, including a record-high premium in the book building process in 2025, reflects positive market sentiment and robust liquidity.

Chris Yang, Senior Director, Head of Valuation and Advisory Services, Beijing, and Head of China REIT Practice Group, commented, “Investors are increasingly drawn to the stable returns and diversification benefits offered by C-REITs. In a financial environment marked by decreasing risk-free rates, which have dropped close to 100 basis points in the last two years, C-REITs offer a compelling alternative. Prospectuses for RE C-REITs project an average dividend yield of 5.0% in the first year of listing, a significant spread over government bonds. This stable, income-generating characteristic is a primary draw for a wide range of investors seeking predictable cashflows.”

Retail sector assets, including shopping malls, outlets, and community commerce centers, have proven particularly attractive. Investors are showing a clear preference for mature, stable assets, focusing on key metrics that indicate long-term viability. Important factors identified by Cushman & Wakefield include asset maturity (5–10 years of operation), high occupancy rates (typically above 90%), and locations within first-tier or core second-tier cities. The remaining land use term (RLUT) is also another critical valuation factor.

Yang added “Looking ahead, the C-REIT market is poised for sustained growth and further integration into China’s broader economic strategy. It provides a crucial mechanism for deleveraging the infrastructure and commercial real estate sector, promoting sustainable urban development, and offering to the public a transparent and regulated vehicle for investing in high-quality infrastructure and commercial real estate assets. As the C-REIT market continues to evolve—highlighted by the recent announcement of asset class expansion to include Grade A office buildings and 4+ star hotels—its role in enabling efficient capital allocation and bolstering the long-term stability of China’s commercial real estate sector is poised to become even more significant.”

Hashtag: #Cushman&Wakefield

The issuer is solely responsible for the content of this announcement.

About Cushman & Wakefield

Cushman & Wakefield (NYSE: CWK) is a leading global commercial real estate services firm for property owners and occupiers with approximately 52,000 employees in nearly 400 offices and 60 countries. In Greater China, a network of 23 offices serves local markets across the region. In 2024, the firm reported revenue of $9.4 billion across its core services of Valuation, Consulting, Project & Development Services, Capital Markets, Project & Occupier Services, Industrial & Logistics, Retail, and others. Built around the belief that Better never settles, the firm receives numerous industry and business accolades for its award-winning culture. For additional information, visit or follow us on LinkedIn.

DJI Redefines Aerial Delivery with DJI FlyCart 100

By
Advertorial Desk
-

Achieve More Delivery with DJI’s Next-Generation Delivery Drone, Carrying Up to 100 kg with Longer Flight Distance and Improved Power Efficiency.

SHENZHEN, China, Dec. 4, 2025 /PRNewswire/ — DJI, the world’s leader in civil drones and creative camera technology, today launches the DJI FlyCart 100 ( FC100 ) to the global market. Building on the industry-defining FlyCart 30, which made aerial delivery possible on Mount Everest, DJI’s next-generation delivery drone features a higher payload capacity of up to 100 kg, faster charging, and an intelligent safety system with LiDAR, a parachute, and multi-sensor obstacle avoidance. For improved flight operations management, DJI is also introducing the DJI Delivery App and the DJI DeliveryHub. 

DJI Redefines Aerial Delivery with DJI FlyCart 100
DJI Redefines Aerial Delivery with DJI FlyCart 100

“DJI continues to innovate to meet industry needs. Even in the early days of aerial delivery, our advanced civilian drone technology has become the trusted solution globally for emergency response, construction, and supply chain logistics – from transporting air tanks and trash on Mount Everest to delivering emergency supplies after the devastating floods,” says Hao Jin, the Head of DJI Delivery Sales at DJI. “With the next-generation DJI FC100, we built a drone that can deliver more – in payload capacity, endurance, and safety – and support more applications across more industries.”

Greater Payload Capacity Up to 100 kg (Max Takeoff Weight Up to 170 kg )

The FC100 is designed to operate in the most challenging environments, climbing mountains and over rivers, lakes, and bays. Building on its predecessor’s coaxial four-axis, eight-blade, multi-rotor configuration, the FC100 features an optimized wing design, 62-inch carbon fiber propellers, and larger motors with more torque. With these improvements, it can carry up to 65 kg payloads for 12 km with the dual-battery configuration – a significant improvement from 30 kg. Similarly, with the emergency single-battery configuration, it can now carry up to 80 kg for 6 km, compared to 40 kg. 

Ultra-Fast Charging

The FC100’s Energy System now supports ultra-fast charging with a C12000 charger or D14000iE generator. Combined with the dual battery hot-swapping and battery redundancy design, operations can continue uninterrupted. Each 41Ah battery can be heated through the DJI Battery Incubator to ensure optimal performance in cold weather. The batteries can work with various chargers indoors and outdoors. 

New Flagship Winch System

The FC100 features the new Flagship Winch System, which is equipped with an electric hook for more efficient loading and unloading. The winch features a 30-meter cable, offering both automatic and manual release and retrieval options. It can also maintain a retractable speed of 1.2 m/s when handling heavy loads, ensuring efficient and reliable operation.

Improved Operational Safety for Multiple Scenarios 

The FC100’s Intelligent Safety System is equipped with multiple sensors, including high-precision LiDAR for terrain mapping, millimeter-wave Radar for all-around detection, and a penta-vision system for better environmental awareness. It also features an integrated parachute that can be opened in an emergency to effectively slow down the touchdown speed to 7m/s and minimize the risk to people and property. Featuring a water- and dust-resistant IP55 rating, the FC100 can operate in temperatures ranging from -20°C to 40°C, withstand winds of up to 12 m/s, and fly at altitudes of up to 6,000 meters.

Stay in Control with the DJI Delivery App and the DJI DeliveryHub

The all-new DJI Delivery App enables pilots to operate the FC100 with their controller, featuring new features such as A-B Route Operation Mode and AR Display. They can also view the drone’s real-time flight status and cargo transport details from the streamlined interface. Meanwhile, DJI DeliveryHub serves as a one-stop air delivery management platform, facilitating efficient multi-platform collaboration. It supports efficient operation planning, comprehensive operation status monitoring, centralized team resource management, and data collection and analysis. FC100 can be customized to support PSDK and high-power interfaces for third-party payloads.

Availability

The FC100 is available for purchase through authorized DJI Delivery dealers. Learn more:https://www.dji.com/flycart-100 

1 All data was measured using a production model in a controlled environment. Product specifications may vary locally to align with local legal and policy frameworks. For more information, please refer to our official website: https://www.dji.com/flycart-100  

NovaBridge Announces Presentation of Ragistomig Expanded Phase 1 Data at ESMO-IO

By
Advertorial Desk
-
  • Ragistomig is a 4-1BB X PD-L1 bispecific antibody, designed to treat patients who are relapsed or refractory to checkpoint inhibitors, a multi-billion dollar drug class hampered by widespread resistance
  • The Phase 1 ragistomig study achieved its objective, as the new Q6W extended dosing interval produced strong anti-tumor efficacy in PD-L1-non-responders, with an improved safety profile
  • The interim results, including immunological data on CD8+ cell proliferation and memory T-cell activation, are expected to be presented in a poster session at ESMO-IO on December 10, 2025

ROCKVILLE, Md., Dec. 4, 2025 /PRNewswire/ — NovaBridge Biosciences (Nasdaq: NBP) (NovaBridge or the Company) a global biotechnology platform company committed to accelerating access to innovative medicines, announced that new data from the expanded Phase 1 dosing study for ragistomig, a 4-1BB X PD-L1 bispecific antibody, will be presented in a poster at the European Society for Medical Oncology – Immuno-Oncology Congress 2025 (ESMO-IO 2025) by co-developer ABL Bio. The poster (Abstract #688) will be presented by Gerald Falchook, MD, Director of the Sarah Cannon Research Institute (SCRI) at HealthONE Denver, on Wednesday, December 10th at 5:30 PM GMT.

“The expanded Phase 1 dosing study achieved its objective of extending the therapeutic window for ragistomig by defining a new dosing schedule that could provide strong anti-tumor efficacy and a more manageable tolerability profile, including improved hepatic safety. The data build on promising Phase 1 data presented at ASCO 2024 and support progression to combination studies which could significantly advance patient care,” said Phillip Dennis, MD, PhD, Chief Medical Officer of NovaBridge.

“Ragistomig was designed to deliver new therapeutic options for patients who have developed resistance or relapsed after treatment with checkpoint inhibitors, a multi-billion dollar drug class that serves as the cornerstone of care for many cancers. We are encouraged by the promising ragistomig advancements and data that will be presented at ESMO-IO and look forward to continuing the program in collaboration with our partner, ABL Bio,” said Sean Fu, PhD, Chief Executive Officer of NovaBridge.

ESMO-IO Meeting information:

  • Title: Phase 1 Clinical Trial of Ragistomig (ABL503/TJ-L14B: PD-L1 × 4-1BB bispecific antibody) Q6W Dosing Balances Favorable Safety and Sustained Efficacy Through Extended Immunologic Memory and Reinvigoration of CD8+ T Cells
  • Abstract #688
  • Date and Time: Wednesday, December 10th at 5:30 PM GMT

A copy of the poster will be available here after the session. To review an overview of the Phase 1 dose escalation data, click here.

About Ragistomig

Ragistomig (also known as ABL503) is a differentiated novel bispecific that integrates a single-chain, Fc-silent PD-L1 segment as a tumor engager and 4-1BB segment as a conditional T cell activator. It was developed using ABL Bio’s “Grabody-T” bispecific antibody platform technology to overcome resistance to PD-(L)1 inhibition and stimulate 4-1BB activation only in the presence of PD-L1 expressing tumor cells, to minimize the risk of off-tumor toxicity. Preclinical studies demonstrated that the bispecific antibody showed better anti-tumor activity than its single-agent components. A Phase 1 dose expansion study (NCT04762641) is currently being conducted in the U.S. and South Korea. The study was designed with a primary endpoint of defining the dose-limiting toxicity and adverse event profile of ragistomig, as well as to observe the objective response rate, pharmacokinetic and immunogenicity profiles and other secondary endpoints.

Ragistomig (also known as ABL503) is being jointly developed with ABL Bio

ASCO 2024: the 2024 American Society for Clinical Oncology Annual Meeting; Q6W: every six weeks

About NovaBridge

NovaBridge is a global biotechnology platform company committed to accelerating access to innovative medicines. We combine deep business development expertise with agile translational clinical development to identify, accelerate, and advance breakthrough assets. By bridging science, strategy, and execution, NovaBridge enables transformative therapies to progress rapidly from discovery toward patients in need.

The Company’s differentiated pipeline is led by givastomig, a potential best-in-class, bispecific antibody (Claudin 18.2 x 4-1BB), and VIS-101, a second-in-class, potentially best-in-class bifunctional biologic, targeting VEGF-A and ANG2.

Givastomig conditionally activates T cells via the 4-1BB signaling pathway in the tumor microenvironment where Claudin 18.2 is expressed. Givastomig is being developed to treat Claudin 18.2-positive gastric cancer and other gastrointestinal malignancies. The Company is also collaborating with its partner, ABL Bio, for the development of ragistomig, a bispecific antibody integrating PD-L1 as a tumor engager and 4-1BB as a conditional T cell activator, in solid tumors. Additionally, NovaBridge owns worldwide rights outside of China to uliledlimab, an anti-CD73 antibody that targets adenosine-driven immunosuppression in cancer.

VIS-101 targets VEGF-A and ANG-2 to provide more potent and durable treatment benefits for patients with wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). VIS-101 is currently completing a large, randomized, dose-ranging Phase 2 study for wet AMD. NovaBridge is the majority shareholder of Visara, and Visara controls global rights to VIS-101, outside of Greater China and certain countries in Asia.

For more information, please visit https://www.novabridge.com and follow us on LinkedIn.

Forward Looking Statements

This announcement contains forward-looking statements. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as “will”, “expects”, “believes”, “designed to”, “anticipates”, “future”, “intends”, “plans”, “potential”, “estimates”, “confident”, and similar terms or the negative thereof. NovaBridge may also make written or oral forward-looking statements in its periodic reports to the U.S. Securities and Exchange Commission (the SEC), in its annual report to shareholders, in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Statements that are not historical facts, including statements about the Company’s beliefs and expectations, are forward-looking statements. Forward-looking statements in this press release include, without limitation, statements regarding: the strategy, clinical development, plans, results, safety and efficacy of givastomig and VIS-101 and its other drug candidates, including ragistomg; the strategic and clinical development of NovaBridge’s drug candidates, including givastomig, ragistomig and VIS-101; anticipated clinical milestones and results, and related timing, and the impact of new leadership appointments. Forward-looking statements involve inherent risks and uncertainties that may cause actual results to differ materially from those contained in these forward-looking statements, including but not limited to the following: the Company’s ability to demonstrate the safety and efficacy of its drug candidates; the clinical results for its drug candidates, which may or may not support further development or New Drug Application/Biologics License Application (NDA/BLA) approval; the content and timing of decisions made by the relevant regulatory authorities regarding regulatory approval of the Company’s drug candidates; the Company’s ability to achieve commercial success for its drug candidates, if approved; the Company’s ability to obtain and maintain protection of intellectual property for its technology and drugs; the Company’s reliance on third parties to conduct drug development, manufacturing and other services; the Company’s limited operating history and the Company’s ability to obtain additional funding for operations and to complete the development and commercialization of its drug candidates; and those risks more fully discussed in the “Risk Factors” section in the Company’s annual report on Form 20-F filed with the SEC on April 3, 2025 as well as the discussions of potential risks, uncertainties, and other important factors in the Company’s subsequent filings with the SEC. All forward-looking statements are based on information currently available to the Company. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as may be required by law.

NovaBridge Investor & Media Contacts

PJ Kelleher
LifeSci Advisors
+1-617-430-7579
pkelleher@lifesciadvisors.com

NovaBridge Biosciences
+1-240-745-6330
IR@novabridge.com 

 

Tata Communications Acquires Majority Stake in Commotion Inc., Fast-Tracking AI-Led Transformation Across Its Digital Fabric

By
Advertorial Desk
-

MUMBAI, India, Dec. 4, 2025 /PRNewswire/ — Tata Communications, a leading global communications technology player, today announced that it has acquired 51% stake in Commotion Inc., a leading AI-native Enterprise SaaS Platform company with operations in the US and India.

This acquisition marks a significant step in accelerating AI integration across Tata Communications’ Digital Fabric offerings, particularly within its Customer Interaction Suite, that includes Tata Communications Kaleyra,to deliver contextual and converged AI driven experiences for both customers and employees. Commotion’s orchestration engine will integrate with Kaleyra’s core components — including channels, Kaleyra TX Hub, and CCaaS — to automate and intelligently guide end-to-end customer journeys, shifting engagement from reactive responses to predictive and generative interactions.

Commotion powers global enterprises with three force-multiplying pillars:

  • Omnichannel CX Automation for real-time, data-driven, hyperpersonalised engagement
  • Voice AI solutions built on ultra-low latency speech-to-speech AI models
  • Business-Ready Autonomous Digital Agents that are compliant, intelligent, policy-aware AI entities that operate continuously across customer-facing and internal enterprise functions

The platform unifies Voice AI, Agentic AI Builder, and Omnichannel Journey Orchestration, enabling brands to automate complex work and deliver real-time, personalised engagement at scale, while simultaneously transforming enterprise operations through AI-powered digital support.

Acquiring Commotion and integrating its capabilities into its Digital Fabric, will further accelerate Tata Communications’ own AI adoption and advance its journey to becoming an AI-first organisation. This development builds on its ongoing efforts to help enterprises shift from AI experimentation to scalable, business-critical transformation.

A. S. Lakshminarayanan, MD & CEO, Tata Communications, said: “This acquisition marks a significant step in our journey to redefine customer experience in the AI era. With Commotion’s capabilities already integrated into Tata Communications Kaleyra, we are seeing phenomenal customer traction. We expect this momentum to further accelerate our evolution into an AI-first organisation, making our Digital Fabric more intelligent, adaptive, and future ready.”

Murali Swaminathan, CEO, Commotion Inc., added: “We are thrilled to announce this significant milestone in our journey. This isn’t just about capital. It’s about conviction, shared purpose, and the power of combining our innovation velocity with Tata Communications’ global reach, trusted brand and digital expertise. Together, we will unlock AI’s full potential in many industry sectors, building solutions that scale responsibly and transform the way the world works. The future isn’t just coming – it’s here, and it’s global.”

The transaction will be executed as a cash-only acquisition on a fully diluted basis through a Stock Purchase Agreement.

To explore this in more detail, please click on the link:
https://www.tatacommunications.com/kaleyra/commotion

About Tata Communications

A part of the Tata Group, Tata Communications (NSE: TATACOMM) (BSE: 500483) is a global digital ecosystem enabler powering today’s fast-growing digital economy in more than 190 countries and territories. Leading with trust, it enables digital transformation of enterprises globally with collaboration and connected solutions, core and next gen connectivity, cloud hosting and security solutions and media services. 300 of the Fortune 500 companies are its customers and the company connects businesses to 80% of the world’s cloud giants. For more information, please visit www.tatacommunications.com

X | LinkedIn | YouTube | Instagram

Forward-looking and cautionary statements

Certain words and statements in this release concerning Tata Communications and its prospects, and other statements, including those relating to Tata Communications’ expected financial position, business strategy, the future development of Tata Communications’ operations, and the general economy in India, are forward-looking statements. Such statements involve known and unknown risks, uncertainties and other factors, including financial, regulatory and environmental, as well as those relating to industry growth and trend projections, which may cause actual results, performance or achievements of Tata Communications, or industry results, to differ materially from those expressed or implied by such forward-looking statements. The important factors that could cause actual results, performance or achievements to differ materially from such forward-looking statements include, among others, failure to increase the volume of traffic on Tata Communications’ network; failure to develop new products and services that meet customer demands and generate acceptable margins; failure to successfully complete commercial testing of new technology and information systems to support new products and services, including voice transmission services; failure to stabilize or reduce the rate of price compression on certain of the company’s communications services; failure to integrate strategic acquisitions and changes in government policies or regulations of India and, in particular, changes relating to the administration of Tata Communications’ industry; and, in general, the economic, business and credit conditions in India. Additional factors that could cause actual results, performance or achievements to differ materially from such forward-looking statements, many of which are not in Tata Communications’ control, include, but are not limited to, those risk factors discussed in Tata Communications Limited’s Annual Reports.

The Annual Reports of Tata Communications Limited are available at www.tatacommunications.com. Tata Communications is under no obligation to, and expressly disclaims any obligation to, update or alter its forward-looking statements.

© 2025 Tata Communications Ltd. All rights reserved.

TATA COMMUNICATIONS and TATA are trademarks or registered trademarks of Tata Sons Private Limited in India and certain countries.

All other third-party trademarks belong to their respective owners.

 

Masan Consumer Announces HoSE Listing Roadmap: Southeast Asia’s Leading FMCG Company Sustains ~20% Profit Compound Annual Growth Rate

By
Advertorial Desk
-

HO CHI MINH CITY, Vietnam, Dec. 4, 2025 /PRNewswire/ — Masan Consumer Corporation (UPCoM: MCH), a subsidiary of Masan Group, today announced its roadmap to list on the Ho Chi Minh City Stock Exchange (“HoSE”) during the “MCH Roadshow – HoSE Migration Announcement”. The Company stated that the migration to HoSE is scheduled for December 2025, marking a significant milestone in its capital market journey. The event comes as Vietnam’s fast-moving consumer goods (“FMCG”) sector enters a new growth cycle, supported by rising disposable income, an expanding middle class, and increasing demand for higher-quality consumer products.

Masan Consumer plans to migrate to HoSE in December 2025.
Masan Consumer plans to migrate to HoSE in December 2025.

Over nearly three decades, Masan Consumer has built one of Vietnam’s most extensive FMCG brand ecosystems. According to Kantar Worldpanel, 98% of Vietnamese households use at least one Masan Consumer product. The Company leads approximately 80% of core seasonings and convenience food categories, including fish sauce, soy sauce, chili sauce, instant noodles, instant coffee, and coffee-flavored energy drinks.

From 2017 to 2024, the Company achieved a revenue CAGR of approximately 13%, while maintaining operating profit margins above 23% despite macro volatility. During 2022–2024, net profit continued to compound at roughly 20% per year, underscoring the Company’s strengthening earnings power. Sustained financial performance across multiple cycles has positioned Masan Consumer among Southeast Asia’s leading FMCG companies, comparable to regional peers that consistently deliver double-digit revenue CAGR and net profit margins above 20%.

These financial results were underpinned by strategic growth drivers that have strengthened the Company’s long-term competitive advantages. In specific, premiumization has emerged as a defining trend in Vietnam’s FMCG industry. Masan Consumer has led this transformation by expanding consumption occasions and enhancing value propositions across categories. CHIN-SU (Seasonings Category), the brand has evolved from traditional dipping sauces to a full cooking solution portfolio, including marinades, cooking sauces, and integrated meal-prep products – significantly increasing household penetration and market size. Meanwhile, with Omachi (Convenience Foods Category), the Company accelerated the shift from a ~US$1 billion instant noodle market to the ~US$17 billion premium convenient meal space, capturing higher-value consumption.

Five power brands—CHIN-SU, Nam Ngu, Omachi, Kokomi, Wake-Up 247—each generate over US$100 million in annual revenue, collectively contributing ~70% of incremental topline growth. Core innovations typically reach Top-3 market share within two years, far outpacing industry norms, reflecting Masan Consumer’s deep consumer insight and nationwide distribution strength. Since 2002, the Company has launched more than 1,200 new products, with innovation contributing roughly 20% of revenue during 2017–2024.

The Company reaches consumers through nearly 500,000 traditional trade outlets and 10,000 modern retail points nationwide. Building on this foundation, Masan Consumer launched the Retail Supreme model in 2024 to enhance control over execution, standardize in-store visibility, optimize inventory, and strengthen engagement with retailers. This tech-enabled model creates an integrated data engine – enhancing assortment planning, optimizing display efficiency, and improving sell-out performance. Combined with the scale and consumer insight of WinCommerce’s WinMart/WinMart+/WiN network, MCH can rapidly test innovations, adjust formulations in real time, and shorten the go-to-market cycle. As Retail Supreme scales nationwide, it is expected to become a sustainable competitive advantage enabling Masan Consumer to serve the evolving needs of over 100 million Vietnamese consumers more efficiently.

From 2018 to 2024, Masan Consumer paid out approximately US$1.5 billion in cash dividends to shareholders while still investing heavily in innovation and distribution expansion. Strong cash flow generation and sustained profitability reinforce the Company’s position as both a growth and defensive asset within Vietnam’s consumer sector.

Beyond the domestic market, Masan Consumer is accelerating its “Go Global” strategy by expanding its footprint across 26 international markets, including the U.S., Japan, South Korea, and Australia. International revenue increased at a ~16% CAGR from 2022 to 2024, achieving an operating margin of ~30% in 2024. The contribution of the international business rose from 1% of revenue in 2020 to 5% in 2025, with a medium-term target of 10–20%.

HOSE Listing – A Commitment to Transparency, Governance, and Sustainable Growth

With a strong brand portfolio, solid premiumization strategy, deep distribution scale, resilient financial foundation, and an experienced leadership team, Masan Consumer is well positioned to maximize long-term shareholder value on HOSE, Vietnam’s largest and most reputable stock exchange. Listing on HOSE reaffirms Masan Consumer’s commitment to operational excellence, enhanced transparency, and best-in-class corporate governance. The listing marks a pivotal milestone that opens a new growth chapter—one where Masan Consumer will continue to strengthen its strategic pillars and deliver sustainable value to consumers and shareholders in the years ahead.

WSPN Completes Global Payment Upgrade: Multi-Currency, Multi-Chain Infrastructure Now Live

By
Advertorial Desk
-

TORTOLA, British Virgin Islands, Dec. 4, 2025 /PRNewswire/ — Worldwide Stablecoin Payment Network (WSPN) today announced the completion of its Global Payment infrastructure upgrade, establishing a comprehensive payment orchestration layer that supports multiple currencies, stablecoins, and blockchain networks through a unified API platform.

What’s New: Expanded Multi-Currency and Multi-Chain Coverage

The upgrade introduces traditional currency support, with USD accessible through Wire and ACH rails, and EUR through SEPA. On the digital asset side, the platform now supports five major stablecoins — USDT, USDC, PYUSD, DAI, and EURC — across four leading blockchain networks: Ethereum, Polygon, Solana and TRON.

“Completing the Global Payment infrastructure upgrade represents a major milestone in our mission to provide institutional-grade payment orchestration,” said Raymond Yuan, Founder and CEO of WSPN. “Businesses can now access a complete payment infrastructure layer that handles the complexity of multi-currency, multi-chain operations through simple API calls.”

How It Works: Complete Payment Infrastructure

Global Payment provides end-to-end payment infrastructure through a single API integration, enabling businesses to orchestrate payment flows while maintaining full control over their operations. The platform enables on-ramp and off-ramp services between fiat and digital assets, cross-chain asset movement, token swapping capabilities, and AutoRamp functionality that enables automated conversions based on predefined parameters.

The solution maintains WSPN’s institutional focus with built-in KYB processes, compliance verification, and enterprise-grade reliability. The API architecture allows for rapid deployment and easy maintenance, eliminating the need for businesses to build and maintain connections with multiple payment processors, blockchain networks, and liquidity providers.

Why It Matters: Simplified Global Payment Operations

Global Payment serves as the foundational infrastructure layer for businesses building payment applications, financial services platforms, or any solution requiring seamless movement of value across traditional and digital financial systems.

By consolidating multi-currency, multi-chain operations into a single integration point, the platform significantly reduces technical complexity and time-to-market. Businesses can now offer comprehensive payment capabilities to their customers without the operational overhead of managing disparate payment systems and blockchain integrations.

For more information about Global Payment or to inquire about API access, visit www.wspn.io or contact WSPN’s business development team.

About WSPN

WSPN is a leading provider of next-generation stablecoin infrastructure, dedicated to building a more secure, efficient, and transparent global payment ecosystem. Our flagship stablecoin, WUSD, is fully backed and pegged 1:1 to the U.S. Dollar, serving as the foundation for a suite of integrated financial solutions. These solutions support a range of financial applications from institutional treasury management to programmable payments and decentralized finance. With a strong focus on transparency, regulatory compliance, and user accessibility, WSPN bridges the gap between Web3 innovation and traditional financial systems, driving the global adoption of stablecoins at scale.

Learn more: www.wspn.io | X | LinkedIn

CreAsia Studio’s My Chef In Crime for VISION+ Unveils Lead Cast; Begins Production In Indonesia

By
Advertorial Desk
-

Starring Roy Sungkono and Sintya Marisca, the 8-episode crime series is now in production for VISION+

JAKARTA, Indonesia, Dec. 4, 2025 /PRNewswire/ — CreAsia Studio, launched by Deepak Dhar and Banijay Entertainment, has announced the lead cast for its upcoming crime drama series, My Chef in Crime Indonesia, which has officially entered production on 26 November 2025 in Jakarta. Commissioned by VISION+, the 8-episode × 40-minute series marks a major milestone for the studio as it builds a slate of innovative, locally inspired scripted formats across Southeast Asia. The show stars Roy Sungkono in the male lead and Sintya Marisca as the female lead, both bringing charisma, depth, and a new on-screen pairing to the Indonesian streaming landscape.

CreAsia Studio's My Chef In Crime for VISION+ Unveils Lead Cast; Begins Production In Indonesia
CreAsia Studio’s My Chef In Crime for VISION+ Unveils Lead Cast; Begins Production In Indonesia

Deepak Dhar, Founder & Group CEO, Banijay Asia and Endemol Shine India, added, “This series represents the kind of creative experimentation we want CreAsia to champion. A crime drama infused with food and comedy is a bold departure from the familiar. With a talented cast, a passionate creative team, and the support of VISION+, we believe My Chef in Crime will set a benchmark for original content in the region.”

“We are excited to create an easy-to-digest crime series with food-related cases, blending two of Southeast Asia’s signature genres,” added Jessica Kam-Engle, EVP & Business Head – SE Asia, CreAsia Studio. “My Chef in Crime reflects our ambition to develop original formats that are rooted in local culture yet resonate universally.”

Sondang Pratama, Director, shared his creative vision for the series: “As a director, my vision for My Chef in Crime stems from the intriguing intersection between two worlds that seem far apart—food and forensic science. The more we explored them, the more we realized how naturally they connect. Cooking, much like forensic investigation, is rooted in scientific precision. That parallel inspired us to craft a crime series that is not only entertaining but also emotionally layered and visually distinctive.”

Currently in production, My Chef in Crime follows a forensic investigator-turned chef who becomes the prime suspect in the murder of his culinary rival. Blending forensic science with the world of food, My Chef in Crime Indonesia introduces audiences to a fresh narrative lens—where culinary artistry meets criminal investigation. My Chef in Crime will premiere exclusively on VISION+ in 2026.

 

Hope Medicine Inc.’s HMI-115 Received U.S. FDA Fast Track Designation, Accelerating Global Development

By
Advertorial Desk
-

HMI-115 received FDA Fast Track Designation based on results from a Phase II clinical trial for endometriosis

Mean dysmenorrhea pain score reduced by 42%

Mean non-menstrual chronic pelvic pain score reduced by 52%

Most patients maintained normal menstrual cycles

No typical peri-menopausal symptoms were reported in patients

No significant changes in bone mineral density or sex hormone levels

SHANGHAI, Dec. 4, 2025 /PRNewswire/ — Hope Medicine Inc. (“HopeMed”), a clinical-stage innovative biopharmaceutical company, today announced that its lead pipeline product, HMI-115, a monoclonal antibody targeting the prolactin receptor, has been granted Fast Track Designation (FTD) by the U.S. Food and Drug Administration (FDA) for the treatment of moderate to severe pain associated with endometriosis.

Previously, HMI-115 had been included in the Breakthrough Therapy Designation (BTD) list by the Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA), intended for the treatment of moderate to severe pain associated with endometriosis. This FDA Fast Track Designation marks a significant milestone in the global development of HMI-115, highlighting its outstanding clinical potential.

The FDA Fast Track Designation is a special program established by the U.S. Food and Drug Administration (FDA), an internationally authoritative regulatory agency, to facilitate the development and expedite the review of drugs intended to treat serious conditions and fill an unmet medical need. According to FDA guidelines, drug candidates granted FTD qualify for more frequent interactions and timely feedback from the FDA during subsequent development and review processes.

The granting of Fast Track Designation was based on the results of a completed global Phase II clinical trial for HMI-115. This trial was an international, multicenter, randomized, double-blind, placebo-controlled dose-finding study designed to evaluate the safety and efficacy of HMI-115 in patients with moderate to severe endometriosis-associated pain over a 12-week treatment period. The study enrolled 108 female patients with surgically diagnosed endometriosis across the United States, Poland, and China. Results showed that HMI-115 achieved statistically significant improvement in moderate to severe endometriosis-associated pain and was well-tolerated overall, with no drug-related serious adverse events reported. Specifically, at the end of the treatment, the least-square-mean dysmenorrhea pain score in the 240 mg every two weeks (q2w) dose group decreased by 42% from baseline, and the non-menstrual chronic pelvic pain score decreased by 52%, both with statistical significance. No typical peri-menopausal symptoms were reported during the study; there were no significant changes in menstrual cycle, bone mineral density, or levels of sex hormones such as estradiol, luteinizing hormone (LH), follicle-stimulating hormone (FSH), and progesterone. The results of this proof-of-concept global Phase II clinical trial have been formally published in The Lancet Obstetrics, Gynaecology & Women’s Health.

Endometriosis is a common gynecological disease characterized by the implantation of endometrial cells outside the uterine cavity, typically presenting as a chronic inflammatory response. The endometrium is the mucosal tissue lining the uterine cavity, which undergoes hormone-dependent changes during the menstrual cycle. Endometriosis is common in women of reproductive age, with symptoms including lower abdominal and pelvic pain, dysmenorrhea, painful intercourse, and infertility. Comprehensive literature reports indicate that approximately 10% of women of reproductive age globally are affected by endometriosis, equating to about 190 million women worldwide; 20%-50% of women with infertility have endometriosis, and 71%-87% of women with chronic pelvic pain have endometriosis. Endometriosis is one of the leading causes of dysmenorrhea, infertility, and chronic pelvic pain. The disease often leads to decreased quality of life, affecting patients’ sexual health, psychological well-being, and social behavior. Globally, the disease represents a potential market size of approximately US$200 billion (according to McKinsey report), with significant unmet medical needs. As a potential first-in-class global treatment for endometriosis, the FDA Fast Track Designation for HMI-115 is expected to accelerate its development, review, and approval process, potentially bringing it to patients worldwide sooner.

About Hope Medicine

Hope Medicine Inc. is a science-driven clinical-stage biopharmaceutical company with research laboratories and offices in Beijing, Shanghai, and Nanjing, China. HopeMed is established on the in-depth expertise in translational medicine and decades of research of Professor Rui-Ping Xiao’s laboratory at the Institute of Molecular Medicine of Peking University. Based on excellent scientific research and to improve the quality of life, HopeMed is committed to the research, development, and commercialization of first-in-class medicines for common and major diseases that threaten human health.

Forward-Looking Statements

This press release contains forward-looking statements that are primarily based on the current outlook, expectations, estimates, and projections of the company’s management team. When using “anticipate,” “believe,” “may,” “design,” “effect,” “assess,” “expect,” “predict,” “target,” “aim,” “purpose” and any other similar words and expressions, in references to the company, the intention of the statement is forward-looking. Forward-looking statements are not guarantee of future performance and subject to risks and uncertainties, many of which are difficult to predict and often beyond the company’s control, which could cause actual results to differ materially from the Company’s expectations discussed in the forward-looking statements. These statements are subject to uncertainties and risks including, but not limited to, the following: the Company’s goals and strategies; the Company’s future business development; changes in technology; economic conditions; reputation and brand; the impact of competition and pricing; government regulations; changes in applicable laws or regulations. The company undertakes no public announcement obligation to update or revise any forward-looking statement in this press release, or to publicly announce any such updates or revisions, to reflect changes in our expectations or any events, circumstances or assumptions that affect these statements.

1...1,5771,5781,579...6,441Page 1,578 of 6,441